Spironolactone 25 mg daily significantly reduced mean daytime systolic blood pressure by 5.4 mmHg compared to placebo in patients with resistant arterial hypertension.
Does spironolactone reduce blood pressure in patients with resistant arterial hypertension?
This review highlights that while spironolactone reduces systolic blood pressure in resistant hypertension, its absolute effect in randomized trials is smaller than previously suggested by observational studies.
Effect estimate: Mean difference -5.4 (95% CI -10.0; -0.8)
Absolute Event Rate: -9.3% vs -3.9%
p-value: p=0.024
Spironolakton je diuretikum, kterĂŠ ĂşÄinkuje jako antagonista mineralokortikoidnĂch receptorĹŻ. Tento pĹehledovĂ˝ ÄlĂĄnek shrnuje vĂ˝sledky publikovanĂ˝ch studiĂ se spironolaktonem u pacientĹŻ s rezistentnĂ arteriĂĄlnĂ hypertenzĂ. Ĺada nerandomizovanĂ˝ch observaÄnĂch studiĂ v poslednĂ dekĂĄdÄ ukazovala na vĂ˝raznĂ˝ antihypertenznĂ ĂşÄinek spironolaktonu. V randomizovanĂ˝ch studiĂch vÄetnÄ nedĂĄvno dokonÄenĂŠ randomizovanĂŠ studie ASPIRANT vĹĄak byl absolutnĂ ĂşÄinek spironolaktonu na krevnĂ tlak vĂ˝raznÄ niŞťà a spironolakton statisticky vĂ˝znamnÄ ovlivĹoval pouze systolickĂ˝ krevnĂ tlak. Jsou takĂŠ diskutovĂĄny moĹžnosti predikce ĂşÄinku spironolaktonu na tlak dle vstupnĂch biochemickĂ˝ch parametrĹŻ pacienta.
Václavík et al. (Wed,) conducted a review in Resistant arterial hypertension (n=117). Spironolactone vs. Placebo was evaluated on Decrease in mean daytime systolic blood pressure on ABPM (Mean difference -5.4, 95% CI -10.0; -0.8, p=0.024). Spironolactone 25 mg daily significantly reduced mean daytime systolic blood pressure by 5.4 mmHg compared to placebo in patients with resistant arterial hypertension.